GlassScriptPhysician profile
Nopporn Unnoppet
NPI 1033371323
$22,261.79
in general payments reported to CMS, 2019-2025
21 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $401 · 2021: $889 · 2022: $1,427 · 2023: $1,746 · 2024: $2,230 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,398 · Food and Beverage: $6,362 · Travel and Lodging: $3,424 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,398.00 |
| Food and Beverage | $6,361.64 |
| Travel and Lodging | $3,423.71 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,064.54 | 2019-2025 | Rinvoq, Skyrizi |
| Astrazeneca Pharmaceuticals LP | $1,128.79 | 2021-2025 | Saphnelo |
| Pfizer INC. | $919.56 | 2019-2024 | |
| Amgen INC. | $691.98 | 2019-2025 | Evenity, Otezla, Krystexxa |
| Horizon Therapeutics Plc | $557.98 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $538.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $469.64 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $426.25 | 2020-2025 | Benlysta |
| Janssen Biotech, INC. | $323.09 | 2020-2025 | Tremfya |
| Ucb, INC. | $254.63 | 2019-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $251.50 | 2019 | |
| Fresenius Kabi USA, LLC | $123.55 | 2023-2024 | Idacio |
| Genentech USA, INC. | $91.18 | 2019 | |
| Medexus Pharma, INC. | $86.81 | 2019-2020 | |
| Lilly USA, LLC | $84.90 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $78.21 | 2023-2024 | Hyrimoz |
| Radius Health, INC. | $67.02 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $36.07 | 2022-2023 | Strensiq |
| Acella Pharmaceuticals, LLC | $30.61 | 2023-2024 | NP Thyroid 60 |
| Aurinia Pharma U.S., INC. | $22.71 | 2025 | Lupkynis |
| Currax Pharmaceuticals LLC | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nopporn Unnoppet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.